Therefore, GSK‐3β activation level is particularly critical in Aβ formation and accumulation, and GSK‐3β inhibition activation may play a therapeutic role in AD by reducing Aβ formation and accumulation. This evidence concerns the gene GSK3B and Alzheimer disease.